Literature DB >> 31632020

Nanodelivery and anticancer effect of a limonoid, nimbolide, in breast and pancreatic cancer cells.

Arjun Patra1,2, Swaha Satpathy1,2, Muhammad Delwar Hussain1.   

Abstract

INTRODUCTION: Nimbolide (Nim), a limonoid obtained from the neem tree, Azadirachta indica, has several pharmacological properties, including anticancer effects in different type of cancers. No drug-delivery system has been reported for enhancing the therapeutic application of this novel hydrophobic molecule.
METHODS: In the present research, poly(lactic-co-glycolic acid) (PLGA) nanoparticles of Nim (Nim-nano) were formulated by nanoprecipitation, characterized for physicochemical properties, and screened for anticancer potential in breast (MCF-7 and MDA-MB-231) and pancreatic (AsPC-1) cancer cell lines.
RESULTS: The Nim-nano had a particle size of 183.73±2.22 nm and 221.20±11.03 nm before and after lyophilization, respectively. Cryoprotectants (mannitol and sucrose) significantly inhibited growth in particle size due to lyophilization. The ζ-potential of the Nim-nano was -22.40±4.40 mV. Drug loading and encapsulation efficiency of Nim-nano were 5.25%±1.12% and 55.67%±12.42%, respectively. The Nim-nano exhibited sustained release of Nim for more than 6 days in PBS (pH 7.4) and showed two- to three-fold enhanced cytotoxicity in breast and pancreatic cancer cell lines compared with free Nim.
CONCLUSION: The Nim-nano formulation has great potential for treatment of cancers, such as pancreatic and breast cancer. Further, the PLGA-polymer surface can be modified by conjugation with polyethylene glycol, receptor-binding ligands (eg, folic acid), and other that which may lead to targeted delivery of Nim in the treatment of cancer.
© 2019 Patra et al.

Entities:  

Keywords:  PLGA; breast cancer; nanoparticles; nimbolide; pancreatic cancer

Mesh:

Substances:

Year:  2019        PMID: 31632020      PMCID: PMC6789415          DOI: 10.2147/IJN.S208540

Source DB:  PubMed          Journal:  Int J Nanomedicine        ISSN: 1176-9114


  53 in total

1.  Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil.

Authors:  Mazen M El-Hammadi; Ángel V Delgado; Consolación Melguizo; José C Prados; José L Arias
Journal:  Int J Pharm       Date:  2016-11-05       Impact factor: 5.875

2.  Nimbolide inhibits invasion and migration, and down-regulates uPAR chemokine gene expression, in two breast cancer cell lines.

Authors:  P Elumalai; A Brindha Mercy; R Arunkamar; G Sharmila; F A Bhat; S Balakrishnan; P Raja Singh; J Arunakaran
Journal:  Cell Prolif       Date:  2014-12       Impact factor: 6.831

3.  Enhancing the in vitro anticancer activity of albendazole incorporated into chitosan-coated PLGA nanoparticles.

Authors:  Bong-Seok Kang; Jin-Seok Choi; Sang-Eun Lee; Joon-Kyung Lee; Tae-Hyeon Kim; Woo Suk Jang; Amolnat Tunsirikongkon; Jin-Ki Kim; Jeong-Sook Park
Journal:  Carbohydr Polym       Date:  2016-12-07       Impact factor: 9.381

4.  PLGA nanoparticles loaded with etoposide and quercetin dihydrate individually: in vitro cell line study to ensure advantage of combination therapy.

Authors:  Smita Pimple; Arehalli S Manjappa; Mukesh Ukawala; R S R Murthy
Journal:  Cancer Nanotechnol       Date:  2012-05-09

5.  Encapsulation of dexamethasone into biodegradable polymeric nanoparticles.

Authors:  Carolina Gómez-Gaete; Nicolas Tsapis; Madeleine Besnard; Amélie Bochot; Elias Fattal
Journal:  Int J Pharm       Date:  2006-11-12       Impact factor: 5.875

6.  Insect antifeedant activity of tetranortriterpenoids from the Rutales. A perusal of structural relations.

Authors:  G Suresh; Geetha Gopalakrishnan; S Daniel Wesley; N D Pradeep Singh; R Malathi; S S Rajan
Journal:  J Agric Food Chem       Date:  2002-07-31       Impact factor: 5.279

7.  Formulation and evaluation of PLGA nanoparticles loaded capecitabine for prostate cancer.

Authors:  Shu-Ben Sun; Ping Liu; Fa-Ming Shao; Qi-Long Miao
Journal:  Int J Clin Exp Med       Date:  2015-10-15

8.  Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency.

Authors:  Xiangrong Song; Yu Zhao; Shixiang Hou; Fangyuan Xu; Rongli Zhao; Junyao He; Zheng Cai; Yuanbo Li; Qiuhong Chen
Journal:  Eur J Pharm Biopharm       Date:  2008-01-19       Impact factor: 5.571

9.  Cancer-linked targets modulated by curcumin.

Authors:  Noor Hasima; Bharat B Aggarwal
Journal:  Int J Biochem Mol Biol       Date:  2012-12-24

Review 10.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

View more
  5 in total

Review 1.  Polymeric Nanoparticles: Exploring the Current Drug Development and Therapeutic Insight of Breast Cancer Treatment and Recommendations.

Authors:  Ali Sartaj; Zufika Qamar; Farheen Fatima Qizilbash; Shadab Md; Nabil A Alhakamy; Sanjula Baboota; Javed Ali
Journal:  Polymers (Basel)       Date:  2021-12-15       Impact factor: 4.329

Review 2.  Exploring the therapeutic potential of Neem (Azadirachta Indica) for the treatment of prostate cancer: a literature review.

Authors:  Neelu Batra; Vigneshwari Easwar Kumar; Roshni Nambiar; Cristabelle De Souza; Ashley Yuen; Uyen Le; Rashmi Verma; Paramita M Ghosh; Ruth L Vinall
Journal:  Ann Transl Med       Date:  2022-07

3.  The Untargeted Phytochemical Profile of Three Meliaceae Species Related to In Vitro Cytotoxicity and Anti-Virulence Activity against MRSA Isolates.

Authors:  Leilei Zhang; Maha M Ismail; Gabriele Rocchetti; Nesrin M Fayek; Luigi Lucini; Fatema R Saber
Journal:  Molecules       Date:  2022-01-10       Impact factor: 4.411

4.  Azadirachtin Attenuates Lipopolysaccharide-Induced ROS Production, DNA Damage, and Apoptosis by Regulating JNK/Akt and AMPK/mTOR-Dependent Pathways in Rin-5F Pancreatic Beta Cells.

Authors:  Annie John; Haider Raza
Journal:  Biomedicines       Date:  2021-12-18

Review 5.  Surface-functionalised hybrid nanoparticles for targeted treatment of cancer.

Authors:  Hasnat Tariq; Syed Ali Imran Bokhari
Journal:  IET Nanobiotechnol       Date:  2020-09       Impact factor: 1.847

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.